Wayne H Winegarden

Business & Economics

Controlling Inflation Requires A Better Policy Mix, Not Business Scapegoating

Thanks to errant fiscal and monetary policies, consumer prices continued their relentless climb in December. Just as predictably, politicians seem to be more interested in “rounding up the usual suspects” rather than implementing the right policy mix that would rein in inflation. Political fecklessness in face of rising prices is
Featured

The Fundamental Flaws of the Third-Party Payer System

Part 1 of the Coverage Denied series documented how distortions in the U.S. healthcare system turned the important financial risk management service of health insurance into a barrier to care and an important driver of health care inflation. The insurance industry’s adverse impact on costs is ironic given its current
Featured

NEW BRIEF: 340B Hospitals More Profitable, Provide Less Charity Care, Receive Unwarranted Subsidies

So-called 340B hospitals whose mission is to help the vulnerable are more profitable and provide less charity care, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market think tank. Click to download “Profiting from 340B” “The
Health Care

NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars

Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market
Featured

New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes

Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system
Drug Pricing

ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls

A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no
California

NEW STUDY: Californians Could Save More Than $2,000 Annually if Lawmakers Enacted Free-Market Energy Policies

If lawmakers acted to alleviate the unnecessary costs from state energy mandates, Californians living through these unprecedented times could save more than $2,000 annually – while still lowering emissions – finds a new study released today by the nonpartisan Pacific Research Institute and Power the Future. Click here to download
Business & Economics

Wayne Winegarden quoted in Washington Examiner on trade wars

Fears that the President’s Trump’s trade war with China will lead to a recession may have faded from the headlines, but economists say it cannot be discounted. “We’re not expecting a recession anytime soon, but, that said, there are a number of headwinds, ranging from slower growth, trade tensions, a gradual erosion
Commentary

Defining a Medicines’ Value versus its Price

When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value
Health Care

Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief

The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical
Business & Economics

Controlling Inflation Requires A Better Policy Mix, Not Business Scapegoating

Thanks to errant fiscal and monetary policies, consumer prices continued their relentless climb in December. Just as predictably, politicians seem to be more interested in “rounding up the usual suspects” rather than implementing the right policy mix that would rein in inflation. Political fecklessness in face of rising prices is
Featured

The Fundamental Flaws of the Third-Party Payer System

Part 1 of the Coverage Denied series documented how distortions in the U.S. healthcare system turned the important financial risk management service of health insurance into a barrier to care and an important driver of health care inflation. The insurance industry’s adverse impact on costs is ironic given its current
Featured

NEW BRIEF: 340B Hospitals More Profitable, Provide Less Charity Care, Receive Unwarranted Subsidies

So-called 340B hospitals whose mission is to help the vulnerable are more profitable and provide less charity care, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market think tank. Click to download “Profiting from 340B” “The
Health Care

NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars

Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market
Featured

New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes

Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system
Drug Pricing

ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls

A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no
California

NEW STUDY: Californians Could Save More Than $2,000 Annually if Lawmakers Enacted Free-Market Energy Policies

If lawmakers acted to alleviate the unnecessary costs from state energy mandates, Californians living through these unprecedented times could save more than $2,000 annually – while still lowering emissions – finds a new study released today by the nonpartisan Pacific Research Institute and Power the Future. Click here to download
Business & Economics

Wayne Winegarden quoted in Washington Examiner on trade wars

Fears that the President’s Trump’s trade war with China will lead to a recession may have faded from the headlines, but economists say it cannot be discounted. “We’re not expecting a recession anytime soon, but, that said, there are a number of headwinds, ranging from slower growth, trade tensions, a gradual erosion
Commentary

Defining a Medicines’ Value versus its Price

When it comes to determining value, the U.S. health care system faces unique challenges. Without a better approach, the twin goals of continued innovation and broad-based drug affordability will be difficult, if not impossible, to maintain. Value assessment models are quickly becoming the approach du jour to overcome these challenges. However, value
Health Care

Much-Publicized Report on Financial Returns on Cancer Treatments Contains Significant Flaws and Biases, Finds New PRI Brief

The World Health Organization (WHO) is advocating that the prices of cancer treatments are excessive, but its report that justifies this conclusion contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief released today by the Center for Medical
Scroll to Top